Omvoh™ (mirikizumab-mrkz) Intravenous

Omvoh IV is covered only as induction therapy for adults (≥18) with moderately-to-severely active ulcerative colitis or Crohn’s disease (including specified pouchitis, enterocutaneous/rectovaginal fistulas, or post-ileocolonic resection) and not for maintenance, with required induction dosing (UC: 300 mg IV at Weeks 0, 4, 8; CD: 900 mg IV at Weeks 0, 4, 8). Approval (limited to 3 months) requires documentation of diagnosis, age, planned induction dosing, prior therapy or qualifying clinical criteria (e.g., trial of one systemic agent or specific antibiotic/probiotic/enema/corticosteroid for pouchitis; or corticosteroid/systemic therapy trial or documented fistula/resection for Crohn’s), and prescription by or consultation with a gastroenterologist.

"Moderately to severely active ulcerative colitis in adults."

Sign up to see full coverage criteria, indications, and limitations.